Ambalal Sarabhai Enterprises Limited (BOM:500009)
India · Delayed Price · Currency is INR | Market Cap | 2.21B -23.3% |
| Revenue (ttm) | 2.03B +8.7% |
| Net Income | 104.58M -22.5% |
| EPS | 1.36 -22.9% |
| Shares Out | 76.63M |
| PE Ratio | 21.25 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 71,762 |
| Average Volume | 129,818 |
| Open | 30.00 |
| Previous Close | 29.18 |
| Day's Range | 28.65 - 30.00 |
| 52-Week Range | 23.12 - 41.45 |
| Beta | -0.14 |
| RSI | 58.68 |
| Earnings Date | May 22, 2026 |
About BOM:500009
Ambalal Sarabhai Enterprises Limited, together with its subsidiaries, manufactures, markets, and supplies pharmaceutical products in India and internationally. The company offers products for oncology, infertility, and uro-gynaec areas; generic and veterinary products; antifungal active ingredient products; vitamin C coated products; and analytical, test, and measuring instruments, as well as supplies finished dosage forms and active pharmaceutical ingredients. It also provides broadcast and professional video/audio, and electronic products. Am... [Read more]
Financial Performance
In fiscal year 2025, BOM:500009's revenue was 1.97 billion, an increase of 13.20% compared to the previous year's 1.74 billion. Earnings were 49.31 million, a decrease of -13.20%.
Financial StatementsNews
EXCLUSIVE: Co-Diagnostics Expands South Asia Reach, Targets $13 Billion Market Opportunity
Co-Diagnostics Inc. (NASDAQ: CODX) on Friday signed an agreement for CoSara Diagnostics Pvt. Ltd , to expand its commercial and distribution territory across South Asia to include Bangladesh, Pakista...